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Somatic activating mutations in the gene encoding the epidermal growth factor receptor(EGFR) are found in a proportion of non–small-cell lung cancers (NSCLCs) and have
been associated with sensitivity of lung tumors to the EGFR tyrosine kinase inhibitors
(TKIs), gefitinib (Iressa; AstraZeneca, London, England) and erlotinib (Tarceva; Genen-
tech, Inc., South San Francisco, CA).1–3 Such mutations occur in the exons (18–21)
encoding the kinase domain of the protein; approximately 90% of such mutations occur
as exon 19 deletions, which eliminate an LREA motif, or as exon 21 missense mutations,
resulting in substitution of arginine for leucine at position 858 (L858R).4 These two types
of mutations also appear to be the dominant mutations that predict sensitivity to
treatment.5 Thus, testing tumors for drug-sensitive EGFR mutations can be relatively
straightforward in the clinic, provided that adequate tissue specimen is available for
analysis and that sensitive, reliable assays have been established.6
Up to now, most research has focused on analysis of DNA from tumor specimens
for EGFR mutations. However, in this issue of the Journal of Thoracic Oncology, Kimura
and colleagues demonstrate that EGFR mutations can also be detected in DNA derived
from the serum of lung cancer patients.7 As part of a trial to evaluate the efficacy and
safety of gefitinib monotherapy in chemotherapy-naive patients with advanced NSCLC,
they collected serum from individuals before and 14 days after the initiation of gefitinib,
and then performed sequencing analysis for EGFR mutations on DNA derived from the
sera. Not only were mutations readily detectable but they were also more frequently
observed in post-treatment samples from patients with a partial response or stable disease
than in those patients with progressive disease. These results suggest that serum EGFR
mutations could be useful as a biomarker for monitoring response to EGFR tyrosine
kinase inhibitors during treatment.
Detection of mutant DNA from the blood of lung cancer patients is not a new
concept. For example, it has been previously shown that mutations in the KRAS oncogene,
which occur in 15 to 30% of NSCLCs, can also be detected in the plasma of individuals
whose tumors harbor such mutations.8 In this previous study, serum analysis also appeared
to show promise for monitoring patient response to therapy, as many patients had KRAS
mutations before treatment that were not detectable after treatment (collected 16 weeks
after treatment). KRAS mutations have also been detected in plasma or serum of patients
with other types of cancer,9 and others have described finding amplifications, microsat-
ellite alterations, gene rearrangements, and epigenetic alterations as well (reviewed in
Johnson and Lo10).
Much work remains to be done before such tests can be used routinely in the clinic.
Methods of DNA extraction and analysis from plasma and/or serum and tumor specimens
need to be standardized; the reproducibility, sensitivity, and specificity of these tests need
to be established in well-designed clinical trials; and the optimum time for posttreatment
collection of blood remains to be determined—none of these were addressed by Kimura
and colleagues. It will also be important to establish whether such tests can be used to
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detect early disease. More likely, though, serum analyses
might be useful for detecting early recurrence in patients who
have undergone resection and know their tumor mutation
status. Moreover, because disease in most patients who ini-
tially respond to treatment with gefitinib or erlotinib eventu-
ally progresses on therapy, it will be interesting to determine
whether markers of drug resistance, such as the T790M
EGFR mutations,11–13 can be detected before either clinical
and/or radiographically documented progression.
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